Darren Snellgrove
Halozyme Therapeutics, Inc. (Nasdaq: HALO) has appointed Darren Snellgrove as Chief Financial Officer, effective June 8, 2026, as the biopharmaceutical company looks to strengthen its financial leadership during a period of continued expansion across its drug delivery technology portfolio.
In his new role, Snellgrove will oversee Halozyme’s global financial operations, including capital allocation, corporate development, and investor relations. He will report directly to President and Chief Executive Officer Helen Torley, who said the appointment brings an experienced financial executive with a strong track record in healthcare and investor engagement.
Torley highlighted Snellgrove’s background in managing large-scale pharmaceutical businesses and his experience shaping investor strategy and portfolio decisions at a global level. She said his leadership will support the company’s efforts to accelerate long-term value creation for shareholders.
Snellgrove joins Halozyme with more than three decades of experience across the biopharmaceutical and medtech sectors. Most recently, he led investor relations at Johnson & Johnson, where he oversaw corporate messaging and engagement with analysts and shareholders while working to strengthen external communications and market positioning for the Fortune 50 healthcare company.
Prior to that, he served as Chief Financial Officer of Johnson & Johnson’s Pharmaceuticals division, a business generating more than $50 billion in annual revenue. In that role, he was responsible for global financial leadership across commercial operations, research and development, supply chain, and business development. His tenure included oversight of major portfolio investments, restructuring initiatives, and strategic transactions.
Earlier in his career, Snellgrove held senior finance leadership positions within Johnson & Johnson’s pharmaceutical R&D and innovation divisions, as well as finance roles at Centocor prior to its acquisition. His background spans corporate finance, mergers and acquisitions, and operational strategy across large-scale healthcare organizations.
Snellgrove said he is joining Halozyme at a pivotal stage in its development, pointing to the company’s technology platform and partner ecosystem as key drivers of long-term growth. He emphasized the company’s role in improving the delivery of biologics and its expanding portfolio of licensing agreements with global pharmaceutical partners.
Halozyme is best known for its ENHANZE drug delivery technology, which uses its proprietary enzyme rHuPH20 to enable subcutaneous administration of injectable therapies. The platform is designed to reduce treatment burden and improve patient convenience by allowing drugs traditionally delivered intravenously to be administered under the skin.
The company said ENHANZE has been used in more than one million patient treatments and is commercialized across over 100 global markets. Its licensing partners include major pharmaceutical companies such as Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol Myers Squibb, argenx, and ViiV Healthcare, among others.
Beyond ENHANZE, Halozyme is expanding its delivery technology portfolio with Hypercon™ and Surf Bio’s hyperconcentration technology, both designed to increase drug concentration and reduce injection volume for biologics. These platforms are intended to broaden the range of therapies that can be delivered subcutaneously, including in at-home or clinical settings.
The company also develops drug-device combination products, including auto-injector technologies aimed at improving convenience, reliability, and patient adherence. Its commercial products include Hylenex® and XYOSTED®, alongside partnered programs with Teva Pharmaceuticals and Viatris affiliate McDermott Laboratories.
Headquartered in San Diego, Halozyme operates additional facilities in New Jersey, Minnesota, and Massachusetts, where it also maintains manufacturing operations.
The CFO appointment comes as Halozyme continues to position itself as a key infrastructure provider in biologic drug delivery, leveraging licensing partnerships and proprietary technologies to expand its footprint across global pharmaceutical markets.